AUSTIN BROWN to Antineoplastic Agents
This is a "connection" page, showing publications AUSTIN BROWN has written about Antineoplastic Agents.
Connection Strength
0.841
-
Lipidomic profiles associated with treatment related hepatotoxicity in children with acute lymphoblastic leukemia. Support Care Cancer. 2026 Feb 17; 34(3):209.
Score: 0.469
-
Development and Validation of a Novel Prediction Model for Hearing Loss From Cisplatin Chemotherapy. J Clin Oncol. 2025 07; 43(19):2173-2183.
Score: 0.111
-
Clinical and demographic factors contributing to asparaginase-associated toxicities in children with acute lymphoblastic leukemia. Leuk Lymphoma. 2022 12; 63(12):2948-2954.
Score: 0.092
-
DNA methylation of a novel PAK4 locus influences ototoxicity susceptibility following cisplatin and radiation therapy for pediatric embryonal tumors. Neuro Oncol. 2017 Oct 01; 19(10):1372-1379.
Score: 0.066
-
SOD2 genetic variant associated with treatment-related ototoxicity in cisplatin-treated pediatric medulloblastoma. Cancer Med. 2015 Nov; 4(11):1679-86.
Score: 0.057
-
The cochlear dose and the age at radiotherapy predict severe hearing loss after passive scattering proton therapy and cisplatin in children with medulloblastoma. Neuro Oncol. 2024 Oct 03; 26(10):1912-1920.
Score: 0.027
-
Effect of sensorineural hearing loss on neurocognitive and adaptive functioning in survivors of pediatric embryonal brain tumor. J Neurooncol. 2020 Jan; 146(1):147-156.
Score: 0.019